Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 13Phase 1/2 13Phase 1 13Phase NA 1Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Carboplatin 16Pemetrexed 15Cisplatin 15Erlotinib Hydrochloride 13icotinib 8Propofol 7Gefitinib 7Gemcitabine 6Docetaxel 6endostar protein 5Saline Solution 5Paclitaxel 5Nivolumab 5Endostatins 5tislelizumab 4lorlatinib 4anlotinib 4Vinorelbine 4Sevoflurane 4Drug Therapy 4Afatinib 4pembrolizumab 3durvalumab 3atezolizumab 3Zoledronic Acid 3Radiotherapy 3Dexamethasone 3Acetaminophen 3trilaciclib 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Injections × Thoracic × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡